Treatment protocols for bacterial endocarditis and infection of electrophysiologic cardiac devices

Biofilms, Infection, and Antimicrobial Therapy

Volumn , Issue , 2005, Pages 427-448

  Stryjewski, Martin E ^a   Ralph Corey, G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890799529     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Cabell, C.H., Jollis, J.G., and Peterson, G.E., et al., Changing patient characteristics and the effect on mortality in endocarditis. Arch. Intern. Med. 162, 90-94. 2002.
2. Cabell, C.H., Heidenreich, P.A., Chu, V.H., et al., Increasing rates of cardiac device infections among Medicare beneficiaries, 1990-1999. Am. Heart. J. 147:582-586, 2004.
3. Wilson, W., Karchmer, A.W., Dajani, A.S., et al., Antibiotic treatment of adults with infective endocarditis due to Streptococci, Enterococci, Staphylococci, and HACEK microorganisms. JAMA 274, 1706-1713, 1995.
4. Korzeniowski, O., and Sande, M.A., The National Collaborative Endocarditis Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann. Intern. Med. 97, 496-503. 1982.
5. Nannini, E.C., Singh, K.V., and Murray, B.E., Relapse of type A β-lactamaseproducing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis. 37, 1194-1198, 2003.
6. Steckelberg, J.M., Rouse, M.S., Tallan, B.M., Henry, N.K., and Wilson, W.R., Relative efficacies of broad-spectrum cephalosporins for treatment of methicillinsusceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob. Agents Chemother. 37, 554-558, 1993.
7. Levine, D.P., Fromm, B., and Reddy, R., Slow response to vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115, 674-680, 1991.
8. Small, P., and Chambers, H., Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34, 1227-1231, 1990.
9. Fortun, J., Navas, E., Martinez-Beltran, J., et al., Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamycin. Clin. Infect. Dis. 33, 120-125, 2001.
10. Ruiz, M.E., Guerrero, I.C., and Tuazon, C., Endocarditis caused by methicillinresistant Staphylococcus aureus endocarditis: treatment failure with linezolid. Clin. Infect. Dis. 35, 1018-1020, 2002.
11. Eliopulos, G.M., Quinupristin/Dalfopristin and Linezolid: evidence and opinion. Clin. Infect. Dis. 36, 473-481, 2003.
12. Drew, R.H., Perfect, J.R., and Srinath, L., et al., Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patient intolerant or failing prior therapy. J. Antimicrob. Chemother. 46, 775-784, 2000.
13. Olsen, K.M., Rebuck, J.A., and Rupp, M.E. Arthralgias and myalgias related to Quinupristin/Dalfopristin administration. Clin. Infect. Dis. 32, e83-86, 2001.
14. Gilbert, D.N., Wood, C.A., and Kimbrough, R.C., The Infectious Diseases Consortium of Oregon. Failure of treatment with teicoplanin at 6 mg/kg/day in patients with Staphylococcus aureus intravascular infections. Antimicrob. Agents Chemother. 35, 79-87, 1991.
15. Sakoulas, G., Eliopoulos, G.M., Alder, J., and Thauvin-Eliopoulos, C., Efficacy of Daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1714-1718, 2003.
16. Mylonakis, E., and Calderwood, S.B., Infective endocarditis in adults. N. Eng. J. Med. 345, 1318-1330, 2001.
17. Chambers, H.F., Miller, T., and Newman, M.D., Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two week combination therapy. Ann. Intern. Med. 109, 619-624, 1988.
18. DiNubile, M.J., Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection users. Ann. Intern. Med. 121, 873-876, 1994.
19. Ribera, E., Gomez-Jimenez, J., Cortes, E., et al., Treatment of right-sided Staphylococcus aureus endocarditis. Ann. Intern. Med. 125, 969-974, 1996.
20. Dworkin, R.J., Lee, B.L., Sande, M.A., et al., Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampin. Lancet 2, 1071-1073, 1989.
21. Petti, C.A., and Fowler, V.G., Staphylococcus aureus bacteremia and endocarditis. Infect. Dis. Clin. N. Am. 16, 413-435, 2002.
22. Williams, I., Venables, W.A., Lloyd D., et al., The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology 143, 2407-2413, 1997.
23. Karchmer, A.W., and Longworth, D.L., Infections of intrcardiac devices. Infect. Dis. Clin. North Am. 16, 477-505, 2002.
24. Rouse, M.S., Wilcox, R.M., Henry, N.K., Steckelberg, J.M., and Wilson, W.R., Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant. Staphylococcus epidermidis. Antimicrob. Agents Chemother. 34, 273-276, 1990.
25. Stanbridge, T.N., and Isalska, B.J., Aspects of prosthetic valve endocarditis. J. Infect. 35, 1-6. 1997.
26. John, M.D.V., Hibberd, P.L., and Karchmer, A.W., Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin. Infect. Dis. 26, 1302-1309, 1998.
27. Calderwood, S.B., Swinski, L.A., Karchmer, A.W., Waternaux, C.M., and Buckley, M.J., Prosthetic valve endocarditis: analysis of factors affecting outcome therapy. J. Cardiovasc. Surg. 92, 776-783, 1986.
28. Caputo, G.M., Archer, G.L., Calderwood, S.B., DiNubile, M.J., and Karschmer, A.W., Native valve endocarditis due to coagulase-negative staphylococci. Clinical and microbiologic features. Am. J. Med. 83, 619-625, 1987.
29. Rocha, J.L., Janoff, E.N., Ellingson, L.A., and Crossley, K.B., Consequences of coagulase-negative staphylococcal endocarditis of native valves. Abstract 276. 41st Annual Meeting of the Infectious Disease Society of America. San Diego, CA, 2003.
30. Drinkovi, D., Morris, A.J., Pottumarthy, S., MacCulloch, D., and West, T., Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J. Antimicrob. Chemother. 52, 820-825, 2003.
31. Arber, N., Militianu, A., Ben-Yehuda A., et al., Native valve Staphylococcus epidermidis endocarditis: report of seven cases and review of the literature. Am. J. Med. 90, 758-762, 1991.
32. Wilson, W.R., Thompson, R.L., Wilkowske, C.J., et al., Short-term therapy for streptococcal infective endocarditis: combined intramuscular administration of penicillin and netilmicin. JAMA 245, 360-363, 1981.
33. Siegel, M., and Timpone, J., Penicillin-resistant Streptococcus pneumoniae endocarditis: a case report and review. Clin. Infect. Dis. 32, 972-974, 2001.
34. Martinez, E., Miro, J.M., Almirante, B., et al., Effect of penicillin-resitance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin. Infect. Dis. 35, 130-139, 2002.
35. Levy, C.S., Kogulan, P., Gill, V.J., et al., Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin. Infect. Dis. 33, 577-579, 2001.
36. Krogstad, D.J., and Parquette, A.R., Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob. Agents Chemother. 17, 965, 1980.
37. Le, T., and Bayer, A., Combination antibiotic therapy for infective endocarditis. Clin. Infect. Dis. 36, 615-621, 2003.
38. Megran, D.W., Enterococcal endocarditis. Clin. Infect. Dis. 15, 63-71. 1992.
39. Watanakunakorn, C., and Bakie, C., Synergism of vancomycin-gentamycin and vancomycin-streptomycin against enterococci. Antimicrob. Agents Chemother. 4, 120-124, 1973.
40. Brandt, C.M., Rouse, M.S., Laue, N.W., et al., Effective treatment of multidrugresistant enterococcal experimental endocarditis with combination of cell wall-active agents J. Infect. Dis. 173, 909-913, 1996.
41. Galvada, J., Miro, J., Torres C., et al., Efficacy of ampicillin plus ceftriaxone or cefotaxime in treatment of endocarditis due to Enterococcus faecalis [abstract L1342]. In: Programs and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, D.C.: American Society of Microbiology, 2001.
42. Murray, B.E., Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342, 710-721, 2000.
43. Mekonen, E.T., Noskin, G.A., Hacek, D.M., and Peterson, L.R., Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb. Drug Resist. 1, 249-253, 1995.
44. McNeil, S.A., Clark, N.M., Chandrasekar, P.H., and Kauffman, C.A., Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (Quinupristin-Dalfopristin). Clin. Infect. Dis. 30, 403-404, 2000.
45. Babcock, H.M., Ritchie, D.J., Christiansen E., et al., Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin. Infect. Dis. 32, 1373-1375, 2001.
46. Akins, R.L. and Rybak, M.J., Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45, 454-459, 2001.
47. Cha, R., and Rybak, M.J., Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diag. Microbiol. and Infect. Dis. 47, 539-546, 2003.
48. Safdar, A., Bryan, C.S., Stinson, S., and Saunders, D.E., Prosthetic valve endocarditis due to vancomycin-resitant Enterococcus faecium: Treatment with chloramphenicol plus minocycline. Clin. Infect. Dis. 34, e61-63, 2002.
49. Levine, D.P., Crane, L.R., and Zervos, Z.M., Bacteremia in narcotic addicts at the Detroit Medical Center II. Infectious endocarditis: a prospective comparative study. Rev. Infect. Dis. 8, 374-396, 1986.
50. Bayer, A.S., Bolger, A.F., Taubert, K.A., et al., Diagnosis and management of infective endocarditis and its complications. Circulation 98, 2936-2948, 1998.
51. Mammana, R.B., Levitsky, S., Sernaque, D., et al., Valve replacement for left-sided endocarditis in drug addicts. Ann. Thorac. Surg. 35, 436, 1983.
52. Fitchtenbaum, C.H., and Smith, M.J., Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem. Clin. Infect. Dis. 14, 353, 1992.
53. Daikops, G.L., Kathopalia, S.B., Lolans, V.T., et al., Long-term oral ciprofloxacin in the treatment of incurable infective endocarditis. Am. J. Med. 84, 786-790, 1988.
54. Raoult, D., Houpikian, P., Tissot Dupont, H., et al., Treatment of Q fever endocarditis. Arch. Intern. Med. 159, 167-173, 1999.
55. Olaison, L., and Pettersson, G., Current best practices and guidelines. Indications for surgical intervention in infective endocarditis. Infect. Dis. Clin. N. Am. 16, 453-475, 2002.
56. Chastre, J., and Trouillet, J.L., Early infective endocarditis on prosthetic valves. Eur. Heart J. 16(Suppl. B), 32-38, 1995.
57. Varheul, H., Renee, B., Vanden Brink, A., et al., Effect of changes in management of active infective endocarditis on outcome in a 25-years period. Am. J. Cardiol. 72, 682-687, 1993.
58. Aranki, S.F., Adams, D.H., Rizzo, R.J., et al., Determinants of early mortality and late survival in mitral valve endocarditis. Circulation 92(SII), 143-149, 1995.
59. Vikram, H.R., Buenconsejo, J., Hasbun, R., and Quagliarello, V.J., Impact of valve surgery on 6-month mortality in adults with complicated left-sided endocarditis. A propensity analysis. JAMA 290, 3207-3214, 2003.
60. Durak, D.T., Evaluating and optimizing outcomes of surgery for endocarditis. JAMA 290, 3250-3251.
61. Mills, J., Utley, J., and Abbott, J., Heart failure in infective endocarditis: predisposing factors, course and treatment. Chest 66, 151-157, 1974.
62. Steckelberg, J.M., Murphy, J.G., Ballard, D., et al., Emboli in infective endocarditis: the prognostic value of echocardiography. Ann. Intern. Med. 114, 635-640, 1991.
63. Mugge, A., Daniel, W.G., Frank, G., and Litchtlen, P.R., Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by transthoracic or transesophageal approach. J. Am. Coll. Cardiol. 14, 631-638, 1989.
64. Cabell, C.H., and Fowler, Jr. V.G., Vegetations in endocarditis: big is bad, but is there more to it? Am. Heart J. 146, 189-190, 2003.
65. Jihad, B., Lebovici, L., Gartman-Israel D., et al., Long-term outcome of infective endocarditis: the impact of the surgical intervention. Clin. Infect. Dis. 33, 1636-1643, 2001.
66. Chamis, A.L., Peterson, G.E., Cabell, C.H., et al., Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 104, 1029-1033, 2001.
67. Chua, J.D., Wilkoff, B.L., Lee, I., et al., Diagnosis and management of infections involving implantable electrophysiologic devices. Ann. Intern. Med. 133, 604-608, 2000.
68. Wilkoff, B.L., Byrd, C.L., Love, C.J., et al., Pacemaker lead extraction with laser sheat: results of the pacing lead extraction with the excimer sheath (PLEXES) trial. J. Am. Coll. Cardiol. 33, 1671-1676, 1999.